VTVT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
vTv Therapeutics Inc (VTVT) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has promising potential in its drug pipeline and positive analyst sentiment, the current technical indicators, financial performance, and lack of immediate positive catalysts suggest that it is better to hold off on investing right now.
The MACD is negatively expanding, indicating bearish momentum. RSI is neutral at 44.301, and the stock is trading below the pivot level of 37.455, with key support at 34.422. Despite bullish moving averages (SMA_5 > SMA_20 > SMA_200), the overall technical outlook is weak.
Analysts are highly optimistic about the company's drug candidate, cadisegliatin, which has Breakthrough Therapy Designation and strong potential for FDA approval. Price targets have been raised significantly, with a bullish outlook on its market adoption and long-term sales.
The stock has experienced a -4.86% decline in regular market trading, and technical indicators suggest bearish momentum. Financials show no revenue growth, a negative net income of -$8.7M, and a gross margin of 0%. Additionally, there is no recent news or significant insider/hedge fund activity to drive short-term momentum.
In Q3 2025, revenue remained at $0 with no YoY growth. Net income improved by 81.85% YoY but remains negative at -$8.7M. EPS improved to -1.08, up 22.73% YoY. Gross margin dropped to 0%, indicating no profitability.
Analysts are bullish on the stock, with multiple Buy ratings and price targets ranging from $47 to $67. The drug candidate cadisegliatin is expected to have strong market potential, with peak sales modeled at $2.15B by 2037.
